{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T06:32:47Z","timestamp":1794378767966,"version":"4.9.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T00:00:00Z","timestamp":1707868800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Umea University"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Women's Health"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>This study aimed to evaluate clinically relevant improvement after conservative self-management of urinary incontinence via a mobile app. It further aimed to establish Minimum Important Differences (MIDs) based on the severity and type of urinary incontinence.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Data was collected in a prospective cohort study that evaluated the freely available app T\u00e4t\u00ae. The app provided pelvic floor muscle training (PFMT) and life-style advice. Non-pregnant, non-postpartum women (\u2265\u200918 years) who downloaded the app to treat urinary incontinence were included, if they completed the Patient Global Impression of Improvement (PGI-I) question at the 3-month follow-up (<jats:italic>n<\/jats:italic>\u2009=\u20091,733). Participants answered the International Consultation on Incontinence Questionnaire (ICIQ-UI SF) at baseline and after 3 months. The score change was analysed for correlation (Spearman) with the PGI-I. We then analysed one-way ANOVAs to determine whether there were significant differences between the groups based on the answers to the PGI-I. The MID was set to the mean change of the group that selected the answer \u201ca little better\u201d to the PGI-I question.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>The one-way ANOVA showed significant differences between PGI-I groups (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.001). The MID for the general group was set to 1.46 (95% Confidence Interval [CI] 1.26\u20131.67). In the sub-group analyses, a MID for the group with slight incontinence could not be determined. For the group with moderate severity the MID was determined to be 1.33 (95% CI 1.10\u20131.57) and for the severe\/very severe group it was 3.58 (95% CI 3.08\u20134.09). Analysis of different types of incontinence showed no difference in MIDs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The MID for self-management via a mobile app was lower than previously established MIDs, but differed depending on baseline severity. This study shows that MIDs need adjustment for baseline severity and treatment intensity when interpreting clinical trial results. If using MIDs as exact numbers, the study population and the treatment must be comparable.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12905-024-02947-x","type":"journal-article","created":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T09:02:23Z","timestamp":1707901343000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Minimum important difference of the ICIQ-UI SF score after self-management of urinary incontinence"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1745-6808","authenticated-orcid":false,"given":"Emma","family":"Nystr\u00f6m","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ina","family":"Asklund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lindam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Samuelsson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,14]]},"reference":[{"key":"2947_CR1","first-page":"4","volume-title":"Incontinence","author":"I Milsom","year":"2017","unstructured":"Milsom I, Altman D, Cartwright R, Lapitan MC, Nelson R, Sj\u00f6str\u00f6m S, et al. Epidemiology of urinary incontinence (UI) and other lower urinary tract symptoms (LUTS), pelvic organ prolaps (POP), and anal incontinence (AI). In: Abrams P, Cardozo L, Wagg A, Wein A, editors. Incontinence. 6th ed. Bristol, UK: ICI-ICS. International Continence Society; 2017. pp. 4\u2013142.","edition":"6"},{"key":"2947_CR2","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1007\/s11136-006-0020-1","volume":"15","author":"SI Saarni","year":"2006","unstructured":"Saarni SI, H\u00e4rk\u00e4nen T, Sintonen H, Suvisaari J, Koskinen S, Aromaa A, et al. The impact of 29 chronic conditions on health-related quality of life: a general population survey in Finland using 15D and EQ-5D. Qual Life Res. 2006;15:1403\u201314.","journal-title":"Qual Life Res"},{"key":"2947_CR3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1007\/s00192-009-0976-9","volume":"21","author":"BT Haylen","year":"2010","unstructured":"Haylen BT, de Ridder D, Freeman RM, Swift SE, Berghmans B, Lee J, et al. An International Urogynecological Association (IUGA)\/International Continence Society (ICS) joint report on the terminology for female pelvic floor dysfunction. Int Urogynecol J. 2010;21:5\u201326.","journal-title":"Int Urogynecol J"},{"key":"2947_CR4","doi-asserted-by":"publisher","first-page":"1592","DOI":"10.1001\/jama.2017.12137","volume":"318","author":"ES Lukacz","year":"2017","unstructured":"Lukacz ES, Santiago-Lastra Y, Albo ME, Brubaker L. Urinary incontinence in women: a review. JAMA. 2017;318:1592\u2013604.","journal-title":"JAMA"},{"key":"2947_CR5","first-page":"2549","volume-title":"Incontinence","author":"P Abrams","year":"2017","unstructured":"Abrams P, Andersson K-E, Apostolidis A, Birder L, Bliss D, Brubaker L, et al. Recommendations of the International Scientific Committee:evaluation and treatment of urinary incontinence, pelvic organ prolapse and faecal incontinence. In: Abrams P, Cardozo L, Wagg A, Wein A, editors. Incontinence. 6th ed. Bristol, UK: I CI-ICS. International Continence Society; 2017. pp. 2549\u2013612.","edition":"6"},{"key":"2947_CR6","unstructured":"Castro-Diaz D, Robinson D, Bosch R, Constantini E, Cotterill N, Espu\u00f1a-Pons M et al. Patient-Reported Outcome Assessment. In: Abrams P, Cardozo L, Wagg A, Wein A, editors. Incontinence. 6th edition ed. Bristol, UK: ICI-ICS. International Continence Society; 2017. p. 541\u2009\u2013\u200998."},{"key":"2947_CR7","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1111\/bju.14121","volume":"121","author":"R Lim","year":"2018","unstructured":"Lim R, Liong ML, Leong WS, Yuen KH. Which outcome measures should be used in stress urinary incontinence trials? BJU Int. 2018;121:805\u201310.","journal-title":"BJU Int"},{"key":"2947_CR8","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1002\/nau.20041","volume":"23","author":"K Avery","year":"2004","unstructured":"Avery K, Donovan J, Peters TJ, Shaw C, Gotoh M, Abrams P. ICIQ: a brief and robust measure for evaluating the symptoms and impact of urinary incontinence. Neurourol Urodyn. 2004;23:322\u201330.","journal-title":"Neurourol Urodyn"},{"key":"2947_CR9","unstructured":"Mokkink LB, Prinsen CA, Patrick DL, Alonso J, Bouter LM, de Vet HC et al. COSMIN Study Design checklist for Patient-reported outcome measurement instruments 2019 [Available from: https:\/\/www.cosmin.nl\/wp-content\/uploads\/COSMIN-study-designing-checklist_final.pdf."},{"key":"2947_CR10","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1002\/nau.22533","volume":"34","author":"LT Sirls","year":"2015","unstructured":"Sirls LT, Tennstedt S, Brubaker L, Kim HY, Nygaard I, Rahn DD, et al. The minimum important difference for the International Consultation on Incontinence Questionnaire-urinary incontinence short form in women with stress urinary incontinence. Neurourol Urodyn. 2015;34:183\u20137.","journal-title":"Neurourol Urodyn"},{"key":"2947_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.urology.2019.08.004","volume":"133","author":"R Lim","year":"2019","unstructured":"Lim R, Liong ML, Lim KK, Leong WS, Yuen KH. The Minimum clinically important difference of the International Consultation on Incontinence questionnaires (ICIQ-UI SF and ICIQ-LUTSqol). Urology. 2019;133:91\u20135.","journal-title":"Urology"},{"key":"2947_CR12","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1002\/nau.22657","volume":"34","author":"E Nystr\u00f6m","year":"2015","unstructured":"Nystr\u00f6m E, Sj\u00f6str\u00f6m M, Stenlund H, Samuelsson E. ICIQ symptom and quality of life instruments measure clinically relevant improvements in women with stress urinary incontinence. Neurourol Urodyn. 2015;34:747\u201351.","journal-title":"Neurourol Urodyn"},{"key":"2947_CR13","doi-asserted-by":"crossref","unstructured":"Schad F, Thronicke A. Real-world evidence-current developments and perspectives. Int J Environ Res Public Health. 2022;19(16).","DOI":"10.3390\/ijerph191610159"},{"key":"2947_CR14","doi-asserted-by":"publisher","first-page":"e040819","DOI":"10.1136\/bmjopen-2020-040819","volume":"11","author":"P Rygh","year":"2021","unstructured":"Rygh P, Asklund I, Samuelsson E. Real-world effectiveness of app-based treatment for urinary incontinence: a cohort study. BMJ Open. 2021;11:e040819.","journal-title":"BMJ Open"},{"key":"2947_CR15","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1002\/nau.20674","volume":"28","author":"A Klovning","year":"2009","unstructured":"Klovning A, Avery K, Sandvik H, Hunskaar S. Comparison of two questionnaires for assessing the severity of urinary incontinence: the ICIQ-UI SF versus the incontinence severity index. Neurourol Urodyn. 2009;28:411\u20135.","journal-title":"Neurourol Urodyn"},{"key":"2947_CR16","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1067\/mob.2003.379","volume":"189","author":"I Yalcin","year":"2003","unstructured":"Yalcin I, Bump RC. Validation of two global impression questionnaires for incontinence. Am J Obstet Gynecol. 2003;189:98\u2013101.","journal-title":"Am J Obstet Gynecol"},{"key":"2947_CR17","doi-asserted-by":"publisher","first-page":"836","DOI":"10.1002\/nau.20379","volume":"26","author":"M Espu\u00f1a-Pons","year":"2007","unstructured":"Espu\u00f1a-Pons M, Dilla T, Castro D, Carbonell C, Casariego J, Puig-Clota M. Analysis of the value of the ICIQ-UI SF questionnaire and stress test in the differential diagnosis of the type of urinary incontinence. Neurourol Urodyn. 2007;26:836\u201341.","journal-title":"Neurourol Urodyn"},{"key":"2947_CR18","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1097\/NNR.0b013e318251d8f6","volume":"61","author":"LC Welch","year":"2012","unstructured":"Welch LC, Botelho EM, Joseph JJ, Tennstedt SL. A qualitative inquiry of patient-reported outcomes: the case of lower urinary tract symptoms. Nurs Res. 2012;61:283\u201390.","journal-title":"Nurs Res"},{"key":"2947_CR19","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1007\/s00192-014-2473-z","volume":"26","author":"J Labrie","year":"2015","unstructured":"Labrie J, Lagro-Janssen AL, Fischer K, Berghmans LC, van der Vaart CH. Predicting who will undergo surgery after physiotherapy for female stress urinary incontinence. Int Urogynecol J. 2015;26:329\u201334.","journal-title":"Int Urogynecol J"},{"key":"2947_CR20","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.ejogrb.2014.06.020","volume":"180","author":"I Diez-Itza","year":"2014","unstructured":"Diez-Itza I, Espu\u00f1a-Pons M, GISPEM GdIdDdSPeM. Evaluating the results of stress urinary incontinence surgery with objective and subjective outcome measures. Eur J Obstet Gynecol Reprod Biol. 2014;180:68\u201371.","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"key":"2947_CR21","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1002\/nau.21098","volume":"30","author":"P Hilton","year":"2011","unstructured":"Hilton P, Robinson D. Defining cure. Neurourol Urodyn. 2011;30:741\u20135.","journal-title":"Neurourol Urodyn"},{"key":"2947_CR22","doi-asserted-by":"publisher","first-page":"e17114","DOI":"10.2196\/17114","volume":"8","author":"NJ Wessels","year":"2020","unstructured":"Wessels NJ, Hulshof L, Loohuis AMM, van Gemert-Pijnen L, Jellema P, van der Worp H, et al. User experiences and preferences regarding an app for the treatment of urinary incontinence in Adult women: qualitative study. JMIR Mhealth Uhealth. 2020;8:e17114.","journal-title":"JMIR Mhealth Uhealth"},{"key":"2947_CR23","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S0895-4356(03)00044-1","volume":"56","author":"RD Crosby","year":"2003","unstructured":"Crosby RD, Kolotkin RL, Williams GR. Defining clinically meaningful change in health-related quality of life. J Clin Epidemiol. 2003;56:395\u2013407.","journal-title":"J Clin Epidemiol"},{"key":"2947_CR24","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1016\/0197-2456(89)90005-6","volume":"10","author":"R Jaeschke","year":"1989","unstructured":"Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407\u201315.","journal-title":"Control Clin Trials"}],"container-title":["BMC Women's Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-024-02947-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12905-024-02947-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12905-024-02947-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,14]],"date-time":"2024-02-14T09:02:34Z","timestamp":1707901354000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcwomenshealth.biomedcentral.com\/articles\/10.1186\/s12905-024-02947-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,14]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["2947"],"URL":"https:\/\/doi.org\/10.1186\/s12905-024-02947-x","relation":{},"ISSN":["1472-6874"],"issn-type":[{"value":"1472-6874","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,14]]},"assertion":[{"value":"28 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The implementation study was approved by the Regional Ethical Review Board, Ume\u00e5 (number 2012-325-31\u00a0M with amendments number 2014-389-32\u00a0M, 2016-80-32\u00a0M, 2017-405-32\u00a0M and 2020\u201304898) and the specific analysis conducted in this study was approved by the Swedish Ethical Review Authority (number 2020\u201304898). Informed consent was provided by all participants by ticking a box and submitting the questionnaires after reading the study information.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"This manuscript does not include any information from which any individual could be identified.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The logos T\u00e4t and T\u00e4t.nu are registered as trademarks by The Swedish Patent and Registration office for eContinence AB, a Swedish e-health company founded in July 2021, with the aim to maintain, spread, commercialize, and further develop the apps created within the research project T\u00e4t.nu (eContinence.se). Eva Samuelsson, Emma Nystr\u00f6m and Ina Asklund are cofounders and shareholders of eContinence AB. Eva Samuelsson is also the Chairman and Managing Director of the company. Anna Lindam has no conflicts of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"118"}}